849811-78-5

Basic information

• Product Name: Pitavastatin Methyl Ester
• Synonyms: Pitavastatin Methyl Ester;(3R,5S,E)-Methyl 7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoate;Methyl (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoate;DOLM;(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid methyl ester;sodium,(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
• CAS NO: 849811-78-5
• Molecular Formula: C₂₆H₂₆FNO₄
• Molecular Weight: 435.4873432
• Mol File: 849811-78-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Pitavastatin Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pitavastatin Methyl Ester(849811-78-5)
• EPA Substance Registry System: Pitavastatin Methyl Ester(849811-78-5)

Safety Data

• Hazardous Substances Data: 849811-78-5(Hazardous Substances Data)

Usage

Uses

Pitavastatin Methyl Ester is the methyl ester derivative of Pitavastatin (P531000, Ca Salt); a competitive inhibitor of HMG-CoA reductase and an antilipemic agent.

Upstream product

• 1343494-43-8 (R)-1-benzyl 7-methyl 5-(tert-butyldimethylsilyloxy)-3-oxoheptanedioate 
• 1343494-44-9 (R)-5-(tert-butyldimethylsilyloxy)-7-methoxy-3,7-dioxoheptanoic acid 
• 1885-29-6 anthranilic acid nitrile 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 352-34-1 4-fluoro-1-iodobenzene 
• 140164-51-8 methyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-yl)acetate 
• 164576-45-8 (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid methyl ester 

Downstream Products

• 147526-32-7 pitavastatin calcium salt 
• 147526-32-7 pitavastatin 
• 1213706-08-1 (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid (R)-NEA salt 

Relevant articles and documents

The synthesis of [18F]pitavastatin as a tracer for hOATP using the Suzuki coupling

Fluorine-18 labeled radiotracers, such as [18F]fluorodeoxyglucose, can be used as practical diagnostic agents in positron emission tomography (PET). Furthermore, the properties of pharmaceuticals can be enhanced significantly by the introduction of fluorine groups into their original structures, and significant progress has been made during the last three decades towards the development of practical procedures for the introduction of fluorine. The replacement of the fluorine atoms present in pharmaceuticals with radioactive 18F atoms is a rational approach for designing novel PET tracers. As a fluorine-containing pharmaceutical agent, pitavastatin has attracted considerable interest from researchers working in the life sciences because it can act as an antihyperlipidemic agent as well as a substrate for hepatic organic anion transporting polypeptides (hOATP). With this in mind, it was envisaged that [18F]pitavastatin would be used as an excellent imaging agent for hOATP, which prompted us to investigate the synthesis of this agent. Herein, we report a practical method for the synthesis of [18F]pitavastatin by the Suzuki coupling reaction of p-iodofluorobenzene and a quinoline boronate derivative, with the desired product being formed in a radiochemical yield of 12 ± 3% (decay corrected from [18F]fluoride ions, n = 3). This journal is

PROCESS FOR PREPARING STATINS

Process for the preparation of β-ketoester synthetic intermediates useful in the preparation of statins, in particular Pitavastatin.